Viridian Therapeutics, Inc.VRDNNASDAQ
Loading
Other Income/Expenses (Net) Over TimeContracting
Percentile Rank92
3Y CAGR+67.4%
Studio
Year-over-Year Change

Net other income and expenses outside core operations

3Y CAGR
+67.4%/yr
vs +84.7%/yr prior
Acceleration
-17.2pp
Decelerating
Percentile
P92
Near historical high
vs 3Y Ago
4.7x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$20.79M-28.5%
2024$29.09M+74.0%
2023$16.72M+277.3%
2022$4.43M+1306.3%
2021$315000.00+194.0%
2020$-335000.00-416.0%
2019$106000.00-72.2%
2018$381000.00+1805.0%
2017$20000.00+112.0%
2016$-166000.00-